<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d392" origId="Desipramine"><sentence id="DrugDDI.d392.s0" origId="s0" text="1."/><sentence id="DrugDDI.d392.s1" origId="s1" text="Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);"><entity id="DrugDDI.d392.s1.e0" origId="s1.p1" charOffset="0-5" type="drug" text="Drugs"/><entity id="DrugDDI.d392.s1.e1" origId="s1.p3" charOffset="21-30" type="drug" text="P450 2D6"/><entity id="DrugDDI.d392.s1.e2" origId="s1.p6" charOffset="63-67" type="drug" text="drug"/><entity id="DrugDDI.d392.s1.e3" origId="s1.p8" charOffset="110-134" type="drug" text="debrisoquin hydroxylase"/><pair id="DrugDDI.d392.s1.p0" e1="DrugDDI.d392.s1.e0" e2="DrugDDI.d392.s1.e1" interaction="?"/><pair id="DrugDDI.d392.s1.p1" e1="DrugDDI.d392.s1.e0" e2="DrugDDI.d392.s1.e2" interaction="?"/><pair id="DrugDDI.d392.s1.p2" e1="DrugDDI.d392.s1.e0" e2="DrugDDI.d392.s1.e3" interaction="?"/><pair id="DrugDDI.d392.s1.p3" e1="DrugDDI.d392.s1.e1" e2="DrugDDI.d392.s1.e2" interaction="?"/><pair id="DrugDDI.d392.s1.p4" e1="DrugDDI.d392.s1.e1" e2="DrugDDI.d392.s1.e3" interaction="?"/><pair id="DrugDDI.d392.s1.p5" e1="DrugDDI.d392.s1.e2" e2="DrugDDI.d392.s1.e3" interaction="?"/></sentence><sentence id="DrugDDI.d392.s2" origId="s2" text="reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available."><entity id="DrugDDI.d392.s2.e0" origId="s2.p26" charOffset="48-65" type="drug" text="P450 2D6 isozyme"/></sentence><sentence id="DrugDDI.d392.s3" origId="s3" text="Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses."><entity id="DrugDDI.d392.s3.e0" origId="s3.p37" charOffset="69-94" type="drug" text="tricyclic antidepressants"/></sentence><sentence id="DrugDDI.d392.s4" origId="s4" text="Depending on the traction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA)."><entity id="DrugDDI.d392.s4.e0" origId="s4.p45" charOffset="29-33" type="drug" text="drug"/><entity id="DrugDDI.d392.s4.e1" origId="s4.p47" charOffset="49-58" type="drug" text="P450 2D6"/><pair id="DrugDDI.d392.s4.p0" e1="DrugDDI.d392.s4.e0" e2="DrugDDI.d392.s4.e1" interaction="?"/></sentence><sentence id="DrugDDI.d392.s5" origId="s5" text="In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o."><entity id="DrugDDI.d392.s5.e0" origId="s5.p61" charOffset="21-26" type="drug" text="drugs"/><entity id="DrugDDI.d392.s5.e1" origId="s5.p64" charOffset="56-63" type="drug" text="isozyme"/><pair id="DrugDDI.d392.s5.p0" e1="DrugDDI.d392.s5.e0" e2="DrugDDI.d392.s5.e1" interaction="?"/></sentence><sentence id="DrugDDI.d392.s6" origId="s6" text="metabolizers."/><sentence id="DrugDDI.d392.s7" origId="s7" text="An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy."><entity id="DrugDDI.d392.s7.e0" origId="s7.p82" charOffset="112-117" type="drug" text="drugs"/></sentence><sentence id="DrugDDI.d392.s8" origId="s8" text="The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;"><entity id="DrugDDI.d392.s8.e0" origId="s8.p84" charOffset="4-9" type="drug" text="drugs"/><entity id="DrugDDI.d392.s8.e1" origId="s8.p87" charOffset="23-42" type="drug" text="cytochrome P450 2D6"/><entity id="DrugDDI.d392.s8.e2" origId="s8.p96" charOffset="96-105" type="drug" text="quinidine"/><pair id="DrugDDI.d392.s8.p0" e1="DrugDDI.d392.s8.e0" e2="DrugDDI.d392.s8.e1" interaction="?"/><pair id="DrugDDI.d392.s8.p1" e1="DrugDDI.d392.s8.e0" e2="DrugDDI.d392.s8.e2" interaction="?"/><pair id="DrugDDI.d392.s8.p2" e1="DrugDDI.d392.s8.e1" e2="DrugDDI.d392.s8.e2" interaction="?"/></sentence><sentence id="DrugDDI.d392.s9" origId="s9" text="cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide)."><entity id="DrugDDI.d392.s9.e0" origId="s9.p98" charOffset="0-10" type="drug" text="cimetidine"/><entity id="DrugDDI.d392.s9.e1" origId="s9.p105" charOffset="45-54" type="drug" text="P450 2D6"/><entity id="DrugDDI.d392.s9.e2" origId="s9.p107" charOffset="66-81" type="drug" text="antidepressants"/><entity id="DrugDDI.d392.s9.e3" origId="s9.p108" charOffset="83-97" type="drug" text="phenothiazines"/><entity id="DrugDDI.d392.s9.e4" origId="s9.p112" charOffset="148-158" type="drug" text="flecainide"/><pair id="DrugDDI.d392.s9.p0" e1="DrugDDI.d392.s9.e0" e2="DrugDDI.d392.s9.e1" interaction="?"/><pair id="DrugDDI.d392.s9.p1" e1="DrugDDI.d392.s9.e0" e2="DrugDDI.d392.s9.e2" interaction="?"/><pair id="DrugDDI.d392.s9.p2" e1="DrugDDI.d392.s9.e0" e2="DrugDDI.d392.s9.e3" interaction="?"/><pair id="DrugDDI.d392.s9.p3" e1="DrugDDI.d392.s9.e0" e2="DrugDDI.d392.s9.e4" interaction="?"/><pair id="DrugDDI.d392.s9.p4" e1="DrugDDI.d392.s9.e1" e2="DrugDDI.d392.s9.e2" interaction="?"/><pair id="DrugDDI.d392.s9.p5" e1="DrugDDI.d392.s9.e1" e2="DrugDDI.d392.s9.e3" interaction="?"/><pair id="DrugDDI.d392.s9.p6" e1="DrugDDI.d392.s9.e1" e2="DrugDDI.d392.s9.e4" interaction="?"/><pair id="DrugDDI.d392.s9.p7" e1="DrugDDI.d392.s9.e2" e2="DrugDDI.d392.s9.e3" interaction="?"/><pair id="DrugDDI.d392.s9.p8" e1="DrugDDI.d392.s9.e2" e2="DrugDDI.d392.s9.e4" interaction="?"/><pair id="DrugDDI.d392.s9.p9" e1="DrugDDI.d392.s9.e3" e2="DrugDDI.d392.s9.e4" interaction="?"/></sentence><sentence id="DrugDDI.d392.s10" origId="s10" text="While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition."><entity id="DrugDDI.d392.s10.e0" origId="s10.p116" charOffset="24-53" type="drug" text="serotonin reuptake inhibitors"/><entity id="DrugDDI.d392.s10.e1" origId="s10.p123" charOffset="69-79" type="drug" text="fluoxetine"/><entity id="DrugDDI.d392.s10.e2" origId="s10.p126" charOffset="97-107" type="drug" text="paroxetine"/><entity id="DrugDDI.d392.s10.e3" origId="s10.p128" charOffset="117-126" type="drug" text="P450 2D6"/><pair id="DrugDDI.d392.s10.p0" e1="DrugDDI.d392.s10.e0" e2="DrugDDI.d392.s10.e1" interaction="?"/><pair id="DrugDDI.d392.s10.p1" e1="DrugDDI.d392.s10.e0" e2="DrugDDI.d392.s10.e2" interaction="?"/><pair id="DrugDDI.d392.s10.p2" e1="DrugDDI.d392.s10.e0" e2="DrugDDI.d392.s10.e3" interaction="?"/><pair id="DrugDDI.d392.s10.p3" e1="DrugDDI.d392.s10.e1" e2="DrugDDI.d392.s10.e2" interaction="?"/><pair id="DrugDDI.d392.s10.p4" e1="DrugDDI.d392.s10.e1" e2="DrugDDI.d392.s10.e3" interaction="?"/><pair id="DrugDDI.d392.s10.p5" e1="DrugDDI.d392.s10.e2" e2="DrugDDI.d392.s10.e3" interaction="?"/></sentence><sentence id="DrugDDI.d392.s11" origId="s11" text="The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved."/><sentence id="DrugDDI.d392.s12" origId="s12" text="Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other."><entity id="DrugDDI.d392.s12.e0" origId="s12.p152" charOffset="63-65" type="drug" text="T"/></sentence><sentence id="DrugDDI.d392.s13" origId="s13" text="Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary)."><entity id="DrugDDI.d392.s13.e0" origId="s13.p169" charOffset="120-130" type="drug" text="fluoxetine"/><entity id="DrugDDI.d392.s13.e1" origId="s13.p174" charOffset="175-192" type="drug" text="active metabolite"/><pair id="DrugDDI.d392.s13.p0" e1="DrugDDI.d392.s13.e0" e2="DrugDDI.d392.s13.e1" interaction="?"/></sentence><sentence id="DrugDDI.d392.s14" origId="s14" text="Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug."><entity id="DrugDDI.d392.s14.e0" origId="s14.p182" charOffset="19-44" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d392.s14.e1" origId="s14.p183" charOffset="50-55" type="drug" text="drugs"/><entity id="DrugDDI.d392.s14.e2" origId="s14.p187" charOffset="73-92" type="drug" text="cytochrome P450 2D6"/><entity id="DrugDDI.d392.s14.e3" origId="s14.p195" charOffset="156-180" type="drug" text="tricyclic antidepressant"/><entity id="DrugDDI.d392.s14.e4" origId="s14.p197" charOffset="194-198" type="drug" text="drug"/><pair id="DrugDDI.d392.s14.p0" e1="DrugDDI.d392.s14.e0" e2="DrugDDI.d392.s14.e1" interaction="?"/><pair id="DrugDDI.d392.s14.p1" e1="DrugDDI.d392.s14.e0" e2="DrugDDI.d392.s14.e2" interaction="?"/><pair id="DrugDDI.d392.s14.p2" e1="DrugDDI.d392.s14.e0" e2="DrugDDI.d392.s14.e3" interaction="?"/><pair id="DrugDDI.d392.s14.p3" e1="DrugDDI.d392.s14.e0" e2="DrugDDI.d392.s14.e4" interaction="?"/><pair id="DrugDDI.d392.s14.p4" e1="DrugDDI.d392.s14.e1" e2="DrugDDI.d392.s14.e2" interaction="?"/><pair id="DrugDDI.d392.s14.p5" e1="DrugDDI.d392.s14.e1" e2="DrugDDI.d392.s14.e3" interaction="?"/><pair id="DrugDDI.d392.s14.p6" e1="DrugDDI.d392.s14.e1" e2="DrugDDI.d392.s14.e4" interaction="?"/><pair id="DrugDDI.d392.s14.p7" e1="DrugDDI.d392.s14.e2" e2="DrugDDI.d392.s14.e3" interaction="?"/><pair id="DrugDDI.d392.s14.p8" e1="DrugDDI.d392.s14.e2" e2="DrugDDI.d392.s14.e4" interaction="?"/><pair id="DrugDDI.d392.s14.p9" e1="DrugDDI.d392.s14.e3" e2="DrugDDI.d392.s14.e4" interaction="?"/></sentence><sentence id="DrugDDI.d392.s15" origId="s15" text="Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required."><entity id="DrugDDI.d392.s15.e0" origId="s15.p201" charOffset="41-46" type="drug" text="drugs"/><entity id="DrugDDI.d392.s15.e1" origId="s15.p206" charOffset="98-122" type="drug" text="tricyclic antidepressant"/><pair id="DrugDDI.d392.s15.p0" e1="DrugDDI.d392.s15.e0" e2="DrugDDI.d392.s15.e1" interaction="?"/></sentence><sentence id="DrugDDI.d392.s16" origId="s16" text="It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6."><entity id="DrugDDI.d392.s16.e0" origId="s16.p222" charOffset="104-108" type="drug" text="drug"/><entity id="DrugDDI.d392.s16.e1" origId="s16.p227" charOffset="137-146" type="drug" text="P450 2D6"/><pair id="DrugDDI.d392.s16.p0" e1="DrugDDI.d392.s16.e0" e2="DrugDDI.d392.s16.e1" interaction="?"/></sentence><sentence id="DrugDDI.d392.s17" origId="s17" text="2."/><sentence id="DrugDDI.d392.s18" origId="s18" text="Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs."><entity id="DrugDDI.d392.s18.e0" origId="s18.p236" charOffset="74-78" type="drug" text="drug"/><entity id="DrugDDI.d392.s18.e1" origId="s18.p240" charOffset="107-122" type="drug" text="anticholinergic"/><entity id="DrugDDI.d392.s18.e2" origId="s18.p242" charOffset="126-147" type="drug" text="sympathomimetic drugs"/><pair id="DrugDDI.d392.s18.p0" e1="DrugDDI.d392.s18.e0" e2="DrugDDI.d392.s18.e1" interaction="?"/><pair id="DrugDDI.d392.s18.p1" e1="DrugDDI.d392.s18.e0" e2="DrugDDI.d392.s18.e2" interaction="?"/><pair id="DrugDDI.d392.s18.p2" e1="DrugDDI.d392.s18.e1" e2="DrugDDI.d392.s18.e2" interaction="?"/></sentence><sentence id="DrugDDI.d392.s19" origId="s19" text="3."/><sentence id="DrugDDI.d392.s20" origId="s20" text="Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited."><entity id="DrugDDI.d392.s20.e0" origId="s20.p248" charOffset="64-84" type="drug" text="antidepressant drugs"/></sentence><sentence id="DrugDDI.d392.s21" origId="s21" text="Thus, if such treatment is essential, the possibility of increased risk relative to benefits should be considered."/><sentence id="DrugDDI.d392.s22" origId="s22" text="4."/><sentence id="DrugDDI.d392.s23" origId="s23" text="If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive."><entity id="DrugDDI.d392.s23.e0" origId="s23.p263" charOffset="3-28" type="drug" text="desipramine hydrochloride"/><entity id="DrugDDI.d392.s23.e1" origId="s23.p268" charOffset="58-77" type="drug" text="psychotropic agents"/><entity id="DrugDDI.d392.s23.e2" origId="s23.p269" charOffset="86-99" type="drug" text="tranquilizers"/><entity id="DrugDDI.d392.s23.e3" origId="s23.p271" charOffset="103-111" type="drug" text="sedative"/><entity id="DrugDDI.d392.s23.e4" origId="s23.p272" charOffset="112-121" type="drug" text="hypnotics"/><entity id="DrugDDI.d392.s23.e5" origId="s23.p281" charOffset="214-222" type="drug" text="sedative"/><entity id="DrugDDI.d392.s23.e6" origId="s23.p282" charOffset="234-245" type="drug" text="desipramine"/><entity id="DrugDDI.d392.s23.e7" origId="s23.p284" charOffset="250-265" type="drug" text="benzodiazepines"/><entity id="DrugDDI.d392.s23.e8" origId="s23.p287" charOffset="273-289" type="drug" text="chlordiazepoxide"/><entity id="DrugDDI.d392.s23.e9" origId="s23.p289" charOffset="293-301" type="drug" text="diazepam"/><pair id="DrugDDI.d392.s23.p0" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e1" interaction="?"/><pair id="DrugDDI.d392.s23.p1" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e2" interaction="?"/><pair id="DrugDDI.d392.s23.p2" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e3" interaction="?"/><pair id="DrugDDI.d392.s23.p3" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e4" interaction="?"/><pair id="DrugDDI.d392.s23.p4" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e5" interaction="?"/><pair id="DrugDDI.d392.s23.p5" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p6" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p7" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p8" e1="DrugDDI.d392.s23.e0" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p9" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e2" interaction="?"/><pair id="DrugDDI.d392.s23.p10" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e3" interaction="?"/><pair id="DrugDDI.d392.s23.p11" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e4" interaction="?"/><pair id="DrugDDI.d392.s23.p12" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e5" interaction="?"/><pair id="DrugDDI.d392.s23.p13" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p14" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p15" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p16" e1="DrugDDI.d392.s23.e1" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p17" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e3" interaction="?"/><pair id="DrugDDI.d392.s23.p18" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e4" interaction="?"/><pair id="DrugDDI.d392.s23.p19" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e5" interaction="?"/><pair id="DrugDDI.d392.s23.p20" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p21" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p22" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p23" e1="DrugDDI.d392.s23.e2" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p24" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e4" interaction="?"/><pair id="DrugDDI.d392.s23.p25" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e5" interaction="?"/><pair id="DrugDDI.d392.s23.p26" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p27" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p28" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p29" e1="DrugDDI.d392.s23.e3" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p30" e1="DrugDDI.d392.s23.e4" e2="DrugDDI.d392.s23.e5" interaction="?"/><pair id="DrugDDI.d392.s23.p31" e1="DrugDDI.d392.s23.e4" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p32" e1="DrugDDI.d392.s23.e4" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p33" e1="DrugDDI.d392.s23.e4" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p34" e1="DrugDDI.d392.s23.e4" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p35" e1="DrugDDI.d392.s23.e5" e2="DrugDDI.d392.s23.e6" interaction="?"/><pair id="DrugDDI.d392.s23.p36" e1="DrugDDI.d392.s23.e5" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p37" e1="DrugDDI.d392.s23.e5" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p38" e1="DrugDDI.d392.s23.e5" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p39" e1="DrugDDI.d392.s23.e6" e2="DrugDDI.d392.s23.e7" interaction="?"/><pair id="DrugDDI.d392.s23.p40" e1="DrugDDI.d392.s23.e6" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p41" e1="DrugDDI.d392.s23.e6" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p42" e1="DrugDDI.d392.s23.e7" e2="DrugDDI.d392.s23.e8" interaction="?"/><pair id="DrugDDI.d392.s23.p43" e1="DrugDDI.d392.s23.e7" e2="DrugDDI.d392.s23.e9" interaction="?"/><pair id="DrugDDI.d392.s23.p44" e1="DrugDDI.d392.s23.e8" e2="DrugDDI.d392.s23.e9" interaction="?"/></sentence><sentence id="DrugDDI.d392.s24" origId="s24" text="Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine."><entity id="DrugDDI.d392.s24.e0" origId="s24.p294" charOffset="9-17" type="drug" text="sedative"/><entity id="DrugDDI.d392.s24.e1" origId="s24.p296" charOffset="22-37" type="drug" text="anticholinergic"/><entity id="DrugDDI.d392.s24.e2" origId="s24.p297" charOffset="53-72" type="drug" text="major tranquilizers"/><entity id="DrugDDI.d392.s24.e3" origId="s24.p300" charOffset="103-114" type="drug" text="desipramine"/><pair id="DrugDDI.d392.s24.p0" e1="DrugDDI.d392.s24.e0" e2="DrugDDI.d392.s24.e1" interaction="?"/><pair id="DrugDDI.d392.s24.p1" e1="DrugDDI.d392.s24.e0" e2="DrugDDI.d392.s24.e2" interaction="?"/><pair id="DrugDDI.d392.s24.p2" e1="DrugDDI.d392.s24.e0" e2="DrugDDI.d392.s24.e3" interaction="?"/><pair id="DrugDDI.d392.s24.p3" e1="DrugDDI.d392.s24.e1" e2="DrugDDI.d392.s24.e2" interaction="?"/><pair id="DrugDDI.d392.s24.p4" e1="DrugDDI.d392.s24.e1" e2="DrugDDI.d392.s24.e3" interaction="?"/><pair id="DrugDDI.d392.s24.p5" e1="DrugDDI.d392.s24.e2" e2="DrugDDI.d392.s24.e3" interaction="?"/></sentence><sentence id="DrugDDI.d392.s25" origId="s25" text="5."/><sentence id="DrugDDI.d392.s26" origId="s26" text="Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants."><entity id="DrugDDI.d392.s26.e0" origId="s26.p303" charOffset="29-39" type="drug" text="cimetidine"/><entity id="DrugDDI.d392.s26.e1" origId="s26.p305" charOffset="44-69" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d392.s26.e2" origId="s26.p310" charOffset="143-168" type="drug" text="tricyclic antidepressants"/><pair id="DrugDDI.d392.s26.p0" e1="DrugDDI.d392.s26.e0" e2="DrugDDI.d392.s26.e1" interaction="?"/><pair id="DrugDDI.d392.s26.p1" e1="DrugDDI.d392.s26.e0" e2="DrugDDI.d392.s26.e2" interaction="?"/><pair id="DrugDDI.d392.s26.p2" e1="DrugDDI.d392.s26.e1" e2="DrugDDI.d392.s26.e2" interaction="?"/></sentence><sentence id="DrugDDI.d392.s27" origId="s27" text="Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6."><entity id="DrugDDI.d392.s27.e0" origId="s27.p314" charOffset="46-71" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d392.s27.e1" origId="s27.p319" charOffset="115-125" type="drug" text="cimetidine"/><entity id="DrugDDI.d392.s27.e2" origId="s27.p325" charOffset="190-214" type="drug" text="tricyclic antidepressant"/><pair id="DrugDDI.d392.s27.p0" e1="DrugDDI.d392.s27.e0" e2="DrugDDI.d392.s27.e1" interaction="?"/><pair id="DrugDDI.d392.s27.p1" e1="DrugDDI.d392.s27.e0" e2="DrugDDI.d392.s27.e2" interaction="?"/><pair id="DrugDDI.d392.s27.p2" e1="DrugDDI.d392.s27.e1" e2="DrugDDI.d392.s27.e2" interaction="?"/></sentence><sentence id="DrugDDI.d392.s28" origId="s28" text="There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents."><entity id="DrugDDI.d392.s28.e0" origId="s28.p333" charOffset="86-111" type="drug" text="tricyclic antidepressants"/><entity id="DrugDDI.d392.s28.e1" origId="s28.p335" charOffset="117-127" type="drug" text="fluoxetine"/><pair id="DrugDDI.d392.s28.p0" e1="DrugDDI.d392.s28.e0" e2="DrugDDI.d392.s28.e1" interaction="?"/></sentence></document>